BioNTech SE and partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. have dosed the first 72 participants in a Phase I trial in China with BioNTech’s nucleoside-modified messenger RNA coronavirus vaccine candidate BNT162b1, following the approval of an IND by the National Medical Products Administration last month.
The two companies are jointly developing the vaccine in China under a $135m alliance signed in March covering mainland China,...







